Shares of Regeneron Pharmaceuticals REGN rose 1.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 18.54% year over year to $7.16, which beat the estimate of $5.98.
Revenue of $1,952,000,000 up by 0.93% from the same period last year, which beat the estimate of $1,740,000,000.
Guidance
Regeneron Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 05, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/eobuvqfq
Price Action
52-week high: $664.64
52-week low: $271.37
Price action over last quarter: Up 18.88%
Company Overview
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.